TeraRecon, a ConcertAI company, has introduced Neuro Suite, an advanced clinical suite powered by artificial intelligence (AI).

The Neuro Suite has been designed for disease triage, and differential diagnostic insights. It will also support care activation in neurological disease states such as neuro-oncology, multiple sclerosis, and dementia.

The platform can be integrated across the entire healthcare organisation, while providing the capability to tackle the obstacles encountered by clinicians while making decisions related to chronic neurological care.

ConcertAI CEO Dr Jeff Elton said: “As an AI-assisted speciality clinical suite solution, Neuro Suite was created to enhance specialists’ ability to assess neurological diseases using various types of imaging modalities.

“ConcertAI’s TeraRecon Eureka Clinical AI offers a portfolio of solutions from the AI leaders in the neurology field, including Combinostics, Imaging Biometrics, and Cercare, creating a first-in-class capability and the only open AI architecture for Clinical AI.”

Combinostics’ algorithm offers advanced brain segmentation analysis for magnetic resonance imaging (MRI) images, to enable accurate assessment of atrophy.

It generates comprehensive reports and incorporates additional features that help determine the probability of a diagnosis and distinguish between various degenerative cerebral conditions such as dementia and Alzheimer’s disease.

Imaging Biometric’s algorithm is designed to offer valuable insights regarding the oxygenation and blood flow of brain tumours, providing crucial information about active tumour regions.

This will help in the diagnosis, monitoring of progression, treatment planning, and evaluation of post-treatment outcomes.

Cercare’s perfusion technology helps understand blood flow and cerebral blood volume to help evaluate neurovascular function for insights into various cerebrovascular and neuro-oncology diseases.